九五至尊网址

Foreign Cooperation

We out-licensed our CTLA-4 antibody (AK107) to Merck for a total considerationof up to US$200 million. According to Frost & Sullivan, we are the first China-based biotech company to out-license a fully internally-discovered monoclonal antibody to a global leading pharmaceutical.

 

We have forged important partnerships, including the most recent one with Chia Tai Tianqing, the principal subsidiary of Sino Biopharm (stock code: 1177), for the joint development and commercialization of our PD-1 antibody drug candidate (penpulimab (AK105)) (the “Sino Biopharm Collaboration”). We believe this will help maximize the commercial value of our penpulimab (AK105), as Sino Biopharm has strong commercial capabilities, including one of China’s largest pharmaceutical sales forces of about 12,000 sales In addition, the Sino Biopharm Collaboration provides that our penpulimab (AK105) is the only PD- 1 antibody that Sino Biopharm can use to develop PD-1-based monotherapy or combinationtherapy.

 

To become a global leader in developing, manufacturing and commercializing innovative, next-generation and affordable therapeutic antibodies for patients wordwide.

Partners
www.782.net-最新网址-九五至尊网址 8455娱乐场门新葡8455最新网站-九五至尊网址 357 cc拉斯维加斯3499-九五至尊网址 澳门新莆京98378com-九五至尊网址 澳门太阳集团2007登陆注册-九五至尊网址 新葡京集团 www.350.vip-九五至尊网址 永利402com官方网站手机版-九五至尊网址 澳门新葡亰平台游戏app官网九五至尊网址-九五至尊网址 95992222九五至尊老品牌-九五至尊网址 mg4155娱乐电子游戏官网-九五至尊网址 伟德betvictot手机版-九五至尊网址 188金宝搏亚洲体育app下载-九五至尊网址 vnsc5858威尼斯城官网-九五至尊网址 188金宝搏亚洲体育app-九五至尊网址 澳门威尼斯人官方网投电子游戏-九五至尊网址 js55658澳门金金沙平台-九五至尊网址 亚洲城vipca88手机版登陆-九五至尊网址 williamhill-九五至尊网址 澳门新葡350vip最新网站-九五至尊网址 95998888九五至尊在线-九五至尊网址